The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme

BJU International

Volumn 100, Issue 3, 2007, Pages 514-517

  Roddam, Andrew W ^a   Hamdy, Freddie C ^b   Allen, Naomi E ^a   Price, Christopher P ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Complexed PSA; Free PSA; Prostate specific antigen; Reflex test; Sensitivity; Specificity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; PATIENT REFERRAL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

AGED; BIOPSY, NEEDLE; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; REFERENCE VALUES; REFERRAL AND CONSULTATION; SENSITIVITY AND SPECIFICITY;

EID: 34547621607     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07000.x     Document Type: Article

References (19)

1. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate- specific antigen level <= 4.0 ng per milliliter. NEJM 2004 350 : 2239 46
2. Gosselaar C, Roobol MJ, Schroder FH. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? BJU Int 2005 95 : 231 7
3. Melia J, Coulson P, Johns L, Moss S. Study to assess the rate of PSA testing in men with no previous diagnosis of prostate cancer. London, UK : Department of Health, 2003
4. Melia J, Moss S, Johns L. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int 2004 94 : 51 6
5. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. NEJM 2003 349 : 335 42
6. Thompson IM, Ankerst DP, Chi C et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA 2005 294 : 66 70
7. Maattanen L, Auvinen A, Stenman UH et al. European randomized study of prostate cancer screening: first- year results of the Finnish trial. Br J Cancer 1999 79 : 1210 4
8. Schroder FH, Denis LJ, Roobol M. The story of the European Randomized study of screening for prostate cancer. BJU Int 2003 92 Suppl 2 1 13
9. Roddam AW, Duffy MJ, Hamdy FC et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml. Systematic review and meta-analysis. Eur Urol 2005 48 : 386 99
10. Melia J, Moss S. Survey of the rate of PSA testing in general practice. Br J Cancer 2001 85 : 656 7
11. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006 175 : 1605 12
12. Soletormos G, Semjonow A, Sibley PE et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 2005 51 : 1342 51
13. Eastham JA, Riedel E, Scardino PT et al. Variation of serum prostate-specific antigen levels - An evaluation of year-to-year fluctuations. JAMA 2003 289 : 2695 700
14. Hamdy FC, Dedman D, Lane A et al. The value of repeat serum PSA measurements in the detection of prostate cancer - experience from the feasibility phase of the UK ProtecT study. J Urol 2006 175 : 153
15. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000 163 : 806 11
16. Holmberg L, Bill-Axelson A, Helgesen F et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. NEJM 2002 347 : 781 9
17. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. NEJM 2005 352 : 1977 84
18. de Koning HJ, Liem MK, Baan CA, Boer R, Schroder FH, Alexander FE, ERSPC. Prostate cancer mortality reduction by screening. Power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002 98 : 268 73
19. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate-cancer screening in the prostate, lung, colorectal and ovarian-cancer screening trial of the national-cancer-institute. J Urol 1994 152 : 1905 9